Lilly Beyond The GLP-1 Story: The Pipeline The Market Is Undercounting

Revenue scaled from $28.3 billion in 2021 to $65.2 billion in 2025. That is 23 percent compound growth. Net income went from $5.6 billion to $20.6 billion in the same window, nearly quadrupling. Operating margin expanded from 28 percent to 45 percent. The scale of the GLP-1 monetisation is historic.

Capex tells the same story from a different angle. Lilly spent $1.9 billion in 2021. By 2023 it was $7.4 billion. In 2025 it ran $7.8 billion. The capex has been almost entirely focused on manufacturing capacity for Mounjaro, Zepbound and forthcoming next-generation incretins. That capex base is now largely built out.

The Medicare coverage change on GLP-1s is the macro news of the month. The precise contours of the formulary decision will drive the 2026-2027 revenue trajectory for Zepbound. The debate over whether Medicare coverage adds or subtracts to the long-run franchise is the noise. The signal is that Lilly's manufacturing capacity gives it the ability to meet whatever demand materialises, and the pricing power on incretins remains significant relative to the legacy diabetes franchise.

Donanemab received FDA approval in 2024 under the Kisunla brand and has been scaling through a healthcare system still working out reimbursement and infusion logistics. The commercial ramp has been slower than consensus modelled in early 2025. That has been priced. What has not been priced is the evolving formulary landscape and the competitive positioning against Leqembi.

Kisunla's differentiation is the fixed-duration dosing protocol. Treatment stops when amyloid plaques clear. That reduces long-term cost and creates a more defensible payer conversation than Leqembi's indefinite dosing. Every quarter of commercial experience strengthens that positioning. Consensus 2028 revenue estimates for Kisunla cluster around $3 to $5 billion. Our base case is $5 to $7 billion.

The analytical pattern here matters. Every major novel mechanism launch in a complex therapeutic area has taken three years longer than initial consensus and reached higher peak sales than initial consensus assumed. Remicade, Humira, Keytruda, Tecentriq. The base rate is consistent.

Lilly's capital allocation discipline has been visible in the dividend track record and the measured pace of buybacks. The dividend yield of 0.65 percent is deceptively low; that reflects the share price expansion, not a lack of capital return. Dividend per share has been growing at mid-single digits throughout the GLP-1 ramp, which is capital allocation restraint given the scale of earnings expansion.

Free cash flow jumped from negative $3.2 billion in 2023, driven by capex commitments, back to $9 billion in 2025. That swing is a function of the capacity build phase ending and the production yield ramping. By 2027 FCF should run at $25 to $30 billion as capex moderates and GLP-1 revenue continues scaling.

The non-GLP-1 pipeline investment has been funded organically. That is important. Lilly has not needed to issue stock or take on leverage to fund the Alzheimer's, autoimmune and oncology programs. The ROIC math on those programs is strong even assuming only modest peak sales.

The direct peer set is Novo Nordisk on GLP-1, Biogen on Alzheimer's, AbbVie and Amgen on autoimmune, Merck and Bristol Myers on oncology. Lilly is the only company with a credible Phase 3 pipeline across all four therapeutic areas simultaneously.

Against Novo Nordisk, the GLP-1 comparison keeps tilting in Lilly's direction. Zepbound efficacy in Phase 3 data has consistently edged Wegovy on weight loss percentage. The oral GLP-1 program at Lilly is further along than at Novo. The manufacturing capacity build is larger at Lilly. None of these advantages are insurmountable for Novo, but each incrementally strengthens the Lilly position.

Against Biogen on Alzheimer's, Leqembi currently leads on commercial launch momentum but Kisunla's fixed-duration protocol is the structural differentiator. The next 18 months of payer negotiations will either confirm or refute that advantage.

Against AbbVie on autoimmune, Lilly has lebrikizumab for atopic dermatitis and a developing pipeline in IL-13 and IL-33 mechanisms. The autoimmune franchise is the smallest of the four legs at Lilly today but has the longest runway because the category TAM continues to expand.

Mounjaro plus Zepbound moving from the current combined run rate of roughly $30 billion toward $50 billion. That requires continued manufacturing scaling and incremental formulary wins.

Kisunla in Alzheimer's moving from the current sub-$1 billion annualised toward $5 to $7 billion by 2028 as physician education and infusion infrastructure mature.

Lebrikizumab in atopic dermatitis and expanding into asthma indications, potentially contributing $3 to $5 billion by 2028.

Oncology pipeline including Verzenio expansion and the orforglipron oral obesity program, potentially contributing another $5 to $8 billion. Orforglipron alone could be a $10 billion franchise if Phase 3 data confirm efficacy and oral convenience drives mix shift.

Add those together and 2028 revenue lands in the $100 to $110 billion range. That is roughly 50 to 65 percent upside from 2025. The multiple does not need to expand for the stock to deliver meaningful returns.